MC
HURA

Merck & Co’s TuHURA Biosciences HURA Stock Holding History

Merck & Co’s Portfolio HURA Stock Details HURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.8K Buy
19,445
+5,495
+39% +$6.73K 0.01% 14
2025
Q4 		$10.6K Hold
13,950
– – ﹤0.01% 12
2025
Q3 		$34.6K Hold
13,950
– – 0.02% 13
2025
Q2 		$31.1K Buy
+13,950
New +$47.1K 0.01% 13

Other funds holding HURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Merck & Co's HURA Position: Q1 2026 in Review

Merck & Co increased its TuHURA Biosciences (HURA) stake by 39% in Q1 2026, buying an estimated $6.73K and bringing the position to 19,445 shares worth $34.8K. The position accounts for 0.01% of the portfolio, ranked #14.

Merck & Co first reported a position in HURA in Q2 2025 and has held it in 4 quarters since. 89 funds tracked by Wall St. Rank hold HURA as of Q1 2026.

  • Merck & Co held 19,445 shares of TuHURA Biosciences worth $34.8K as of Q1 2026.
  • Merck & Co bought 5,495 TuHURA Biosciences shares in Q1 2026, an estimated $6.73K.
  • TuHURA Biosciences made up 0.01% of Merck & Co's portfolio in Q1 2026, its #14 holding.
  • Merck & Co first reported a position in TuHURA Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 89 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.